Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s platform and talks commercialisation.
Can you please start by introducing Congenica to our international readers?
“As well as disease diagnosis, there is a lot that can be done around disease and therapy management using DNA data. For example, management of drug choices and drug interactions are an immediate opportunity."
